New Drugs: Faricimab-svoa (Vabysmo^™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti^™) for Glaucoma and Ocular Hypertension.

Q2 Medicine

Senior Care Pharmacist Pub Date : 2023-12-01 DOI:10.4140/TCP.n.2023.497

Lana Gettman

引用次数: 0

Abstract

Two drugs are covered in this quarterly column. Faricimab-svoa (Vabysmo^™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti^™) for Glaucoma and Ocular Hypertension.

查看原文本刊更多论文

新药:Faricimab-svoa (Vabysmo™)治疗黄斑变性和糖尿病性黄斑水肿，Omidenepag异丙基(Omlonti™)治疗青光眼和高眼压。

本季度专栏包括两种药物。Faricimab-svoa (Vabysmo™)治疗黄斑变性和糖尿病性黄斑水肿，Omidenepag异丙基(Omlonti™)治疗青光眼和高眼压。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Senior Care Pharmacist PHARMACOLOGY & PHARMACY-

CiteScore

1.30

自引率

0.00%

发文量

160

New Drugs: Faricimab-svoa (Vabysmo™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti™) for Glaucoma and Ocular Hypertension.

Abstract

New Drugs: Faricimab-svoa (Vabysmo^™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti^™) for Glaucoma and Ocular Hypertension.